Senseonics Posts Strong Q4 Revenue Growth, Projects 65%+ Revenue Increase for 2026
summarizeSummary
Senseonics Holdings reported strong financial results for Q4 and full-year 2025, with Q4 revenue increasing 72% year-over-year to $14.3 million and full-year revenue reaching $35.3 million. The company also significantly reduced its full-year net loss and provided robust guidance for 2026, projecting global net revenue of $58-$62 million, representing 65-76% year-over-year growth. This positive momentum is driven by key operational achievements, including 103% new patient growth in the U.S., CE Mark approval for Eversense 365 in the EU, and FDA approval to commence a pivotal trial for its Gemini sensor. The strategic decision to bring commercial operations in-house from Ascensia Diabetes Care is a material development aimed at accelerating future growth. Traders will monitor the successful transition of commercial operations and progress on the Gemini trial throughout 2026.
At the time of this announcement, SENS was trading at $8.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $340.4M. The 52-week trading range was $5.25 to $19.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.